Logo image of NMRA

NEUMORA THERAPEUTICS INC (NMRA) Stock Price, Quote, News and Overview

NASDAQ:NMRA - Nasdaq - US6409791000 - Common Stock - Currency: USD

1.09  0 (0%)

NMRA Quote, Performance and Key Statistics

NEUMORA THERAPEUTICS INC

NASDAQ:NMRA (6/10/2025, 12:30:34 PM)

1.09

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High17.19
52 Week Low0.61
Market Cap176.31M
Shares161.75M
Float117.24M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-04 2025-08-04/bmo
IPO09-15 2023-09-15


NMRA short term performance overview.The bars show the price performance of NMRA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 -50

NMRA long term performance overview.The bars show the price performance of NMRA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of NMRA is 1.09 USD. In the past month the price increased by 64.43%. In the past year, price decreased by -88.85%.

NEUMORA THERAPEUTICS INC / NMRA Daily stock chart

NMRA Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 58.03 756.78B
JNJ JOHNSON & JOHNSON 15.59 377.06B
NVO NOVO-NORDISK A/S-SPONS ADR 22.33 356.23B
NVS NOVARTIS AG-SPONSORED ADR 14.3 234.66B
AZN ASTRAZENECA PLC-SPONS ADR 16.8 229.18B
MRK MERCK & CO. INC. 10.4 203.44B
PFE PFIZER INC 7.57 138.24B
SNY SANOFI-ADR 11.24 121.71B
BMY BRISTOL-MYERS SQUIBB CO 6.87 102.67B
GSK GSK PLC-SPON ADR 9.24 83.48B
ZTS ZOETIS INC 27.65 74.10B
HLN HALEON PLC-ADR 22.17 48.88B

About NMRA

Company Profile

NMRA logo image Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 110 full-time employees. The company went IPO on 2023-09-15. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

Company Info

NEUMORA THERAPEUTICS INC

490 Arsenal Way, Suite 200

Watertown MASSACHUSETTS US

Employees: 108

NMRA Company Website

Phone: 18577600900

NEUMORA THERAPEUTICS INC / NMRA FAQ

What is the stock price of NEUMORA THERAPEUTICS INC today?

The current stock price of NMRA is 1.09 USD.


What is the ticker symbol for NEUMORA THERAPEUTICS INC stock?

The exchange symbol of NEUMORA THERAPEUTICS INC is NMRA and it is listed on the Nasdaq exchange.


On which exchange is NMRA stock listed?

NMRA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NEUMORA THERAPEUTICS INC stock?

14 analysts have analysed NMRA and the average price target is 6.73 USD. This implies a price increase of 517.61% is expected in the next year compared to the current price of 1.09. Check the NEUMORA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NEUMORA THERAPEUTICS INC worth?

NEUMORA THERAPEUTICS INC (NMRA) has a market capitalization of 176.31M USD. This makes NMRA a Micro Cap stock.


How many employees does NEUMORA THERAPEUTICS INC have?

NEUMORA THERAPEUTICS INC (NMRA) currently has 108 employees.


What are the support and resistance levels for NEUMORA THERAPEUTICS INC (NMRA) stock?

NEUMORA THERAPEUTICS INC (NMRA) has a support level at 0.77. Check the full technical report for a detailed analysis of NMRA support and resistance levels.


Should I buy NEUMORA THERAPEUTICS INC (NMRA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NEUMORA THERAPEUTICS INC (NMRA) stock pay dividends?

NMRA does not pay a dividend.


When does NEUMORA THERAPEUTICS INC (NMRA) report earnings?

NEUMORA THERAPEUTICS INC (NMRA) will report earnings on 2025-08-04, before the market open.


What is the Price/Earnings (PE) ratio of NEUMORA THERAPEUTICS INC (NMRA)?

NEUMORA THERAPEUTICS INC (NMRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.61).


What is the Short Interest ratio of NEUMORA THERAPEUTICS INC (NMRA) stock?

The outstanding short interest for NEUMORA THERAPEUTICS INC (NMRA) is 11.66% of its float. Check the ownership tab for more information on the NMRA short interest.


NMRA Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to NMRA. When comparing the yearly performance of all stocks, NMRA is a bad performer in the overall market: 96.78% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NMRA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NMRA. While NMRA has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NMRA Financial Highlights

Over the last trailing twelve months NMRA reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS decreased by -4.34% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -100.51%
ROE -113%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-23.53%
Sales Q2Q%N/A
EPS 1Y (TTM)-4.34%
Revenue 1Y (TTM)N/A

NMRA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to NMRA. The Buy consensus is the average rating of analysts ratings from 14 analysts.


Ownership
Inst Owners71.69%
Ins Owners5.58%
Short Float %11.66%
Short Ratio14.07
Analysts
Analysts74.29
Price Target6.73 (517.43%)
EPS Next Y0.08%
Revenue Next YearN/A